Effektiva och accepterade preventivmedel är avgörande för sexuell och reproduktiv hälsa. För att rådge i valet av preventivmetod gäller det att förmedla kunskap och motivation och att komma ihåg att vilken metod som helst är bättre än ingen alls - och att flera metoder kan kombineras. En effektiv preventivmedelsmetod i botten kan kombineras med kondom vid behov mot skydd mot STI, så kallad dubbelt skydd.

Psykiska och somatiska besvär före menstruation är vanligt. Ägglossning är en förutsättning för premenstruella symtom. Därför behöver många kvinnor med PMS och PMDS graviditetsskydd eller behandling för menstruationsrelaterade besvär.

Update: Cutaneous manifestations in COVID-19

Up to 20% of COVID-19 cases have shown skin manifestations. Therefore, in trying to detect and manage the disease earlier and more effectively, it is important to understand how COVID-19 can appear on the skin.

MEST SETE MEDtalks

ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer   Se hele webinar

ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer

<script src="https://fast.wistia.com/embed/medias/4rwno0og6n.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_4rwno0og6n videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/4rwno0og6n/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer&nbsp;&nbsp;&nbsp;<a href='https://bpno.se/webinar/asco-2019-breakthrough-for-cdk4-6-inhibitor-endocrine-therapy-in-premenopausal-patients-with-hr-her2%e2%88%92-advanced-breast-cancer/'>Se hele webinar
ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer

ASCO 2019: Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer

<script src="https://fast.wistia.com/embed/medias/rp2kqsxgnz.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_rp2kqsxgnz videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/rp2kqsxgnz/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ASCO 2019: Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer&nbsp;&nbsp;&nbsp;<a href='https://bpno.se/webinar/asco-2019-updated-overall-survival-for-treatment-of-locally-advanced-or-metastatic-triple-negative-breast-cancer/'>Se hele webinar
ASCO 2019: Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer

EHA 2019: Venetoclax plus obinutuzumab improves PFS and MRD negativity in patients with previously untreated CLL and comorbidities

<script src="https://fast.wistia.com/embed/medias/abbfjgn32v.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_abbfjgn32v videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/abbfjgn32v/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
EHA 2019: Venetoclax plus obinutuzumab improves PFS and MRD negativity in patients with previously untreated CLL and comorbidities&nbsp;&nbsp;&nbsp;<a href='https://bpno.se/webinar/eha-2019-venetoclax-plus-obinutuzumab-improves-pfs-and-mrd-negativity-in-patients-with-previously-untreated-cll-and-comorbidities/'>Se hele webinar
EHA 2019: Venetoclax plus obinutuzumab improves PFS and MRD negativity in patients with previously untreated CLL and comorbidities

EHA 2019: Highly effective combination for initial therapy for young, fit CLL patientsEHA 2019: Highly effective combination for initial therapy for young, fit CLL patients

<script src="https://fast.wistia.com/embed/medias/abbfjgn32v.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_abbfjgn32v videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/abbfjgn32v/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
EHA 2019: Highly effective combination for initial therapy for young, fit CLL patientsEHA 2019: Highly effective combination for initial therapy for young, fit CLL patients&nbsp;&nbsp;&nbsp;<a href='https://bpno.se/webinar/eha-2019-highly-effective-combination-for-initial-therapy-for-young-fit-cll-patientseha-2019-highly-effective-combination-for-initial-therapy-for-young-fit-cll-patients/'>Se hele webinar
EHA 2019: Highly effective combination for initial therapy for young, fit CLL patients

Professor Martin Reck explaining the background for CheckMate 9LA-study and the effect of the combination of nivolumab and ipilimumab + 2 cycles of chemotherapy as first-line treatment of stage IV/recurrent non-small cell lung cancer.

In this MEDtalk Eric J. Small, MD and principal investigator of the SPARTAN study describe what characterizes the group of patients with nonmetastatic castration-resistant prostate cancer?

In this MEDtalk Eric J. Small, MD and principal investigator of the SPARTAN study, explains the clinical benefits from early treatment of patients with nonmetastatic castration-resistant prostate cancer

#Senaste Tidskrift

Non-Melanoma Skin Cancer

Nr. 1 • april 2020
Årgang 1
  • Causes
  • Treatments
  • News